四環醫藥(0460.HK)高開11.76% 與印度熙德隆在製藥領域達成合作框架協議
格隆匯2月12日丨四環醫藥(0460.HK)跳空高開11.76%報1.14港元,盤前成交469.79萬港元,最新總市值108億港元。公司昨晚發佈公告稱,集團與印度註冊公司印度熙德隆製藥有限公司(熙德隆)在製藥領域達成合作框架協議,雙方合作內容包括心腦血管領域、中樞神經領域和抗感染包括新型冠狀病毒(2019-nCoV)等領域藥品的研究與開發、產品註冊、技術轉移、原料供應和本地化生產及銷售方面密切配合、共同發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.